Checa Ros, AnaMuñoz Hoyos, AntonioMolina Carballo, AntonioViejo Boyano, IrisChacín González, MaricarmenBermúdez, ValmoreD'Marco Gascón, Luis GerardoProducción Científica UCH 2023UCH. Departamento de Medicina y CirugíaUCH. Grupo de "Investigación de Enfermedades Cardiorenales y Metabólicas" (IDECAM)2024-09-162024-09-162023-06-28Checa-Ros, A., Muñoz-Hoyos, A., Molina-Carballo, A., Viejo-Boyano, I., Chacín, M., Bermúdez, V. & D’Marco, L. (2023). Low doses of Melatonin to improve sleep in children with ADHD: an open-label trial. Children, vol. 10, i. 7, art. 1121 (28 jun.). DOI: https://doi.org/10.3390/children100711212227-9067 (Electrónico)http://hdl.handle.net/10637/16169Este artículo pertenece al número especial "Sleep Disorders in Children: Presentation, Early Identification and Treatment".Objective. Only a few studies assessing the sleep effects of low doses of melatonin (aMT) have been performed in the past, most of them in adults, and only one in subjects with attention-deficit/hyperactivity disorder (ADHD). The aim of this study was to provide evidence of the changes induced by aMT doses as low as 1 mg in the sleep pattern of pediatric patients with ADHD under treatment with methylphenidate (MPH). Methods. Children and adolescents (7–15 years) with ADHD who were receiving extended-release MPH were recruited. A seven-week sleep diary was collected prior to starting a four-week treatment with 1 mg of aMT (30 min before bedtime). Seven-day actigraphic assessments of sleep were performed before and after treatment. Results. Twenty-seven patients (17 males, 62.96%) participated in the study, who had been receiving MPH for 1.57 (1.11) months. A significant increase in sleep duration (TST) was observed after one month of treatment (463 (49) min to 485 (41) min; p < 0.040), with nonsignificant improvements in sleep-onset latency (SOL), nocturnal awakenings, or sleep efficiency. Only minor adverse effects were reported. Conclusion. Low doses of melatonin (1 mg) are able to increase TST in children and adolescents with ADHD receiving treatment with psychostimulants, with an adequate tolerability profile. Further placebo-controlled trials adjusting the time of aMT administration to the individual circadian profile should explore the effects of low doses of this hormone to shorten SOL in this population of patients.enopen accessMelatoninaMelatoninSueñoSleepTrastorno por Déficit de Atención con Hiperactividad (TDAH)Attention Deficit Hyperactivity Disorder (ADHD)MetilfenidatoMethylphenidateTratamiento médicoMedical treatmentMedicamentoDrugsArtículohttps://doi.org/10.3390/children10071121https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es